Altimmune (ALT) Amortization of Goodwill (2017 - 2018)

Altimmune's (ALT) quarterly Amortization of Goodwill came in at $490676.0 in Q1 2018, down 94.74% on a QoQ basis from $9.3 million in Q4 2017.

Altimmune (ALT) Amortization of Goodwill (2017 - 2018) Analysis & Trends

Altimmune (ALT) has 2 years of Amortization of Goodwill data on file, last reported at $490676.0 in Q1 2018.

On a quarterly basis, Amortization of Goodwill changed N/A year-over-year to $490676.0 in Q1 2018; TTM through Sep 2018 was $9.8 million, a N/A change from a year earlier, with the FY2017 full-year figure at $35.9 million, changed N/A from the prior year.
Amortization of Goodwill for Q1 2018 stood at $490676.0, down from $9.3 million in the prior quarter.
Over the last five years, Amortization of Goodwill for ALT reached as high as $26.6 million in Q3 2017 and fell as low as $490676.0 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Altimmune	7.96 Mn	7.96 Mn	-

Download Data